Search

Piper Sandler raised the firm's price target on Monte Rosa Therapeutics (GLUE) to $20 from $16 and keeps an Overweight rating on the shares after the company announced a global [...]

Monte Rosa Therapeutics (GLUE) announced a global exclusive development and commercialization license agreement with Novartis (NVS) to advance VAV1 MGDs, including MRT-6160. MRT-6160 is currently in an ongoing Phase 1, [...]

Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease programme to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. [...]

Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy patients, who are characterized through carrying specific mutations. This is [...]

Viatris Inc., a global healthcare company, announced it has entered into an exclusive licensing agreement with Lexicon Pharmaceuticals, Inc. for sotagliflozin in all markets outside of the United States and [...]

Amicus Therapeutics (FOLD) announced that it has entered into a License Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals (TEVA). This Agreement resolves the patent litigation brought by Amicus [...]

After AstraZeneca (AZN) announced an exclusive license agreement with CSPC Pharmaceuticals to develop YS2302018 for the treatment of elevated Lp(a), an independent cardiovascular risk factor, Morgan Stanley noted that Silence [...]

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor that [...]

AstraZeneca has entered into an exclusive license agreement with CSPC Pharmaceutical Group Ltd to advance the development of an early stage, novel small molecule Lipoprotein (a) disruptor that has the [...]

Dr. Reddy's Laboratories has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 [...]

Gilead Sciences announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, [...]

Evaxion (EVAX) has entered into an option and licensing agreement with Merck (MRK) for its preclinical vaccine candidates EVX-B2 and EVX-B3, under which Evaxion is expected to receive $3.2M in [...]

Byline: Our Bureau Global pharma major Lupin Limited (Lupin) announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize vonoprazan tablets [...]

Bayer and NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases, reported that they have entered into a collaboration and license agreement [...]

Bayer, a global enterprise with core competencies in the life science fields of health care and nutrition, and NextRNA Therapeutics, a biotechnology company focused on developing transformative medicines to address [...]

Byline: Our Bureau Biocon Biologics has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) that clears the [...]

Bayer and NextRNA Therapeutics announced that they have entered into a collaboration and license agreement to develop small molecule therapeutics targeting, long non-coding RNA, lncRNAs in oncology. Bayer and NextRNA [...]

Conduit Pharmaceuticals (CDT) announced that the company has entered into an agreement with AstraZeneca (AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators, and AZD5904, [...]

Taiwan-based Formosa Pharmaceuticals (Formosa) announced that the company has entered into an exclusive licensing agreement with Apotex Inc. (Apotex), for exclusive rights in Canada to the commercialization of clobetasol propionate [...]

Vir Biotechnology (VIR) 'announced that it has entered into an exclusive worldwide license agreement with Sanofi (SNY) for three clinical-stage masked T-cell engagers and exclusive use of the protease-cleavable masking [...]

Chugai Pharmaceutical Co., Ltd. announced that it has concluded a license agreement with F. Hoffmann-La Roche Ltd (Roche) for inavolisib, a PI3K alpha inhibitor, currently in development for advanced hormone [...]

Opko Health(OPK) announces it has entered into a $250M non-dilutive note purchase agreement with HealthCare Royalty HCRx secured by OPKO's profit share payments from Pfizer received pursuant to its license [...]

Maruho Co., Ltd. announces that it has launched Mitchga subcutaneous (SC) injection 30mg vials (Japanese Accepted Name (JAN): Nemolizumab (genetical recombination), in Japan for the treatment of the following diseases [...]

QurAlis Corporation (QurAlis) announced that it has entered into an exclusive license agreement with Eli Lilly and Company (Lilly) in which QurAlis is granting Lilly global rights to develop and [...]

Pairwise, a company focusing on genetics-based innovation in food and agriculture, launched the first CRISPR food in North America last year - its leafy greens blend, edited with CRISPR for [...]

The company states: 'LadRx is pleased to announce that the Company and NantCell, Inc., together with NantCell's parent company ImmunityBio, Inc., have agreed to a mutual termination of the license [...]

Exelixis, Inc., a globally ambitious oncology company, announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement [...]

Fulcrum Therapeutics, Inc. (Fulcrum), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, announced that it has entered into [...]

Stifel raised the firm's price target on Fulcrum Therapeutics to $22 from $19 and keeps a Buy rating on the shares following the Q1 report. The firm is positive on [...]

Based on its current operating plans, Fulcrum now expects that its cash, cash equivalents, and marketable securities as of March 31, 2024, together with the $80.0 million upfront payment to [...]

Fulcrum Therapeutics (FULC) announced that it has entered into a collaboration and license agreement with Sanofi (SNY) for the development and commercialization of losmapimod, an oral small molecule being investigated [...]

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, has entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include: a co-exclusive license [...]

TD Cowen raised the firm's price target on Novavax (NVAX) to $10 from $5 and keeps a Hold rating on the shares. The firm said its blockbuster licensing deal with [...]

Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company, and Maze Therapeutics, Inc., a biopharmaceutical company, announced the companies have completed an exclusive worldwide license agreement for the rights [...]

JPMorgan analyst Eric Joseph upgraded Novavax (NVAX) to Neutral from Underweight without a price target. The analyst cites the company's COVID-19 vaccine licensing agreement with Sanofi (SNY) for the upgrade. [...]

Novavax (NVAX) has entered into a co-exclusive licensing agreement with Sanofi (SNY). The terms of the agreement include: a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide; [...]

Astellas Pharma Inc, a pharmaceutical company conducting business in more than 70 countries around the world, and Poseida Therapeutics, a clinical-stage biopharmaceutical company advancing differentiated cell therapies and genetic medicines [...]

Chugai Pharmaceutical Co., Ltd. announced that it concluded a license agreement with Roche for zilebesiran, an investigational RNAi therapeutic for hypertension created by Alnylam Pharmaceuticals, Inc. and currently under development [...]

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced it has entered into an exclusive strategic license agreement with Novartis for [...]

Arvinas (ARVN) announced it has entered into an exclusive strategic license agreement with Novartis (NVS) for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC androgen receptor degrader [...]

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries, and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, announced they have entered a strategic licensing [...]

March 25 -- Ancheng Biotechnology Co., Ltd. issued the following news release: 1. Covenant or commitment end date: 113/03/25. 2. Contract or commitment content: Termination of Enarodustat (JTZ-951) Taiwan authorization [...]

Pharmazz announced that it has entered into a license agreement with Dr. Reddy's Laboratories Limited, a global pharmaceutical company, to commercialize a first-in-class innovative drug Centhaquine in India. Developed by [...]

Ono Pharmaceutical Co., Ltd., company develops novel therapeutics to help patients live longer, healthier lives, announced that it has entered into a license agreement with NEX-I, Inc. for NXI-101. NXI-101 [...]